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Abstract
Adenoviruses occupy a substantial place as causative agents of seasonal respiratory 
infections, the most characteristic and severe being epidemic keratoconjunctivitis 
(EKC). Moreover, adenovirus infections are very characteristic with their severe course 
in persons with impaired immune system. The absence of specific anti-adenovirals is 
the major problem, and the development of compounds effective against adenoviruses 
is a principal task. This chapter embraces the results of studies on search for antivirals 
with anti-adenovirus activity, nucleoside/nucleotide analogues and nonnucleoside com-
pounds. Ganciclovir and cidofovir demonstrated effects against adenovirus serotypes in 
vitro and in animal ocular infection models. Cidofovir applied alone or in combination 
with cyclosporine manifested therapeutic effects on patients with EKC in a controlled 
clinical study. We characterized abitylguanide as anti-adenovirus agent in broad-scale 
investigations, including cell culture experiments, and in two double-blind trials with 
very beneficial results.
Keywords: human adenoviruses, antivirals, nucleosides/nucleotides, nonnucleosides, 
mode of action, clinical trials
1. Role of adenoviruses in human pathology
Adenoviruses (AdVs) [1] occupy a significant place in the human pathology [2]. It was estab-
lished that 30–70% of the human population in Europe and North America shows a serop-
revalence to AdVs (cit. in [3]). These viruses are causative agents of wide range of human 
diseases, showing varying tissue tropism. They are generally middle and self-limiting. Among 
them, large place is occupied by acute respiratory tract diseases, especially in children [4]. 
Conjunctivitis is very often registered in these infections. More severe course manifests viral 
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gastroenteritis, especially in infants, as well as hemorrhagic cystitis, and in rare cases, hepa-
titis, myocarditis, meningoencephalitis or nephritis [5, 6]. AdVs are characteristic with their 
severe course in persons with hereditary decreased or impaired immune system: (1) heredi-
tary immunodeficiency; (2) in persons transplant recipients treated with immunosuppressive 
agents; (3) AIDS. In such patients, the abovementioned clinical manifestations are particularly 
prone to disseminated disease frequently show a fatal outcome, in children mortality rate 
attains 83% [7–9]. EKC is another serious and very frequent AdV induced disease, extremely 
often with social importance [10–14].
The major problem of AdVs infections is the absence of chemotherapeutic agents not only for 
the clinical practice, but even the absence at strong anti-adenovirals in experimental research. 
This is pointed in all manuals of virology considering AdVs and AdV-induced infections, in 
the review articles and even in all encyclopedic sources. Evidently, development of an effec-
tive antiviral treatment is a principal task.
This chapter presents a concentrated view on the investigations of experimental chemother-
apy of AdV infections and results of their clinical application (Table 1).
Compound name Chemical structure Target Way of administration and 
clinical trial
Cidofovir AdV DNA polymerase Local application in EKC  
patients




Controlled clinical pilot study 
of combination with  
cyclosporine
Brincyclovir AdV DNA polymerase Oral application
CHIMERIX
Phase II clinical trial
(S)-HPMPA AdV DNA chain 
elongation
(S)-HPMPO-DAPy AdV DNA polymerase
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Compound name Chemical structure Target Way of administration and 
clinical trial
Ganciclovir AdV DNA synthesis, 




Three double-blind trials: two 
in US and one in Germany 
(40 placebo and 40 ZIRGAN 
treated each) 
GCV in combination with the 
microbicide povidon-iodine
Zalcitabine
Alovudine AdV DNA polymerase
Trifluridine DNA synthesis Local application
Vidarabine DNA synthesis
Ribavirin • Inhibition of inosin-
5-MP dehydrogenese 
(decreased GTP pools)
• Viral polymerases 
inhibition (RNA cap-
ping activity of viral 
transcripts)
• Lethal mutagenesis of 
viral RNA genomes 
(“error catastrophe”)
General application in 
immunocompromized patients
Abitylguanide-HCl Ligand of AdV capsid 
proteins
Local application in EKC patients
ADENOSTATIN COLLYRIUM
Two placebo-controlled 
randomised trials on 349 
EKC patients (151 and 198, 
respectively) carried out 
in 1973/74; three placebo-
controlled trials in latest 80th 
years




2.1. Cidofovir [(S)-HPMPC; (S)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine; 
VISTID]
The antiviral effect of cidofovir is based on its transformation in the infected cells in di- and 
triphosphate and such way becoming an alternative substrate of the AdV DNA polymerase 
possessing higher affinity compared to cellular DNA polymerases (I, II and III) [15]. Sequence 
changes in a conserved region of the AdV DNA polymerase were established at cidofovir-
resistant AdV mutants [16].
Cidofovir IC
50
 values in cell culture testing versus broad spectrum of AdVs are within 0.8–
17 μg/ml [17]. In in vivo testing in ocular infection with AdV (type C) of New Zealand rabbits 
and cotton rats the compound treatment is efficacious when administered as 0.5–1% eye drops 
Compound name Chemical structure Target Way of administration and 
clinical trial
15D8 Ligand of precursors of 
terminal protein pTP, 




Alter RNA splicing EIA 
activity gene early in AdV 
infection (late proteins E4 
and F6 and the major late 





Inhibits AdV cysteine 
protease (indispensable 






Table 1. Compounds manifesting activity against human adenoviruses.
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[18–20]. Romanowski and Gordon [21] found efficacy of topical 0.5% cidofovir on several 
human adenoviruses (AdV1, AdV5 and AdV6) in the New Zealand rabbit ocular model. AdV 
type B and type C-induced pneumonia registered in mice and in cotton rats [22] could be used 
for in vivo treatment with antivirals.
2.2. Brincyclovir (BCV; hexadecyloxypropyl-cidofovir; CMX001)
This compound is a lipidic conjugate of cidofovir. It prevents AdV induced mortality in a 
permissive, immunosuppressed animal model [23].
2.3. (S)-HPMPA [(S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine
Its anti-AdV effect has the same mechanism as cidofovir—inhibition of the AdV DNA chain 
elongation [24].
2.4. USC-187 (alkyl tyrosinamide-ester prodrug of HPMPA)
This compound proved active against multiple AdV serotypes in vitro and was effective 
versus AdV-C6 in hamsters immunosuppressed by cyclophosphamide. Administered orally 
USC-187 prevented or significantly decreased mortality, virus titers and liver pathology up 
to 4 days post AdV i.v. challenge. Applied in a respiratory AdV-C6 challenge model USC-187 
manifested symptoms of toxicity [25].
2.5. (S)-HPMPO-DAPy [2,4-diamino-6-[3-hydroxy-2-(phosphonomethoxy)-propoxy]
pyrimidine)
The compound anti-AdV activity registered was slightly inferior than that of cidofovir and 
HPMPA [26].
2.6. (S)-2242 [2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine
In vitro manifested a marked activity on AdV replication with selectivity index exceeding 
cidofovir [26].
2.7. Ganciclovir (GCV)
This compound is known as a drug approved for the treatment of herpes infection (cytomega-
lovirus infection especially) was reported to be effective against human AdVs in vitro [27]. In 
cell culture GCV inhibits AdV5 replication and expression of late genes [28]. These authors 
established a marked effect of 3% GCV in cotton rat eyes, on replication and pathology of this 
virus [28] Ying et al. [29] tested the GCV administered locally for prophylactic or therapeutic 
effect in immunosuppressed (by cyclophosphamide) Syrian hamsters intravenously infected 
with human AdV5 and was established that the compound suppresses AdV5 replication in 
the liver and AdC5-induced pathology of infected hamsters thus mitigated the consequences 
of the AdV infection. It was showed that GCV inhibits AdV5 DNA synthesis and late gene 
expression. The slight increase in GCV phosphorylation in AdV infected cells established by 
Chemotherapy of Adenovirus Infections
http://dx.doi.org/10.5772/intechopen.79160
17
Ying et al. [29] could be a result of slightly elevated cellular thymidine kinase activity, higher in 
testing in vivo. These authors hypothesize the direct inhibition of the AdV DNA polymerase as 
a possible mechanism of GCV suppressive effect on AdV DNA synthesis.
2.8. Zalcitabine (2′3’-dideoxycytidine, ddC)
This anti-HIV compound possesses a marked anti-AdV activity, even stronger than cidofovir 
in ocular AdV infections in laboratory animals [30].
2.9. Alovudine
Alovudine (FddT) manifest in vitro (IC
50
 = 0.2–0.7 μg/ml) and in vivo (mouse model of AdV 
pneumonia) anti-AdV activity of the order of that of cidofovir [26, 31].
2.10. Trifluridine (3FT) and vidarabine (Vira-A)
Anti-AdV activity of these anti-HSV compounds is moderate, and the current data on their 
testing are controversial [32–34].
2.11. Ribavirin (1-ß-D-ribofuranosyl-1,2,4-triazole-3-carboxamide)
This triazole nucleoside was described initially by Sidwell et al. [35]. Numerous studies were 
carried out on the mode of action of this compound manifesting activity toward large spec-
trum of viruses (predominantly RNA containing) belonging to different taxonomic groups. 
However, there are no data about the mechanism of anti-AdV effect of ribavirin. Several 
different mechanisms were formulated about the antiviral effects of this compound: (1) 
decreased levels of intracellular guanosine triphosphate pools based on inhibition of cellular 
inosine-5-monophosphate dehydrogenase; (2) inhibition of viral polymerases; (3) inhibition 
of RNA capping activity of viral transcripts; (4) lethal mutagenesis of the viral RNA genomes, 
also termed “error catastrophe,” based on the induction of increased viral mutation rate over 
the critical error rate (especially expressed on enterovirus replication) via incorporation of 
the compound into newly synthesized genomes; (5) immunomodulatory role particularly on 
adaptive immune responses—the compound is inducer of the helper-T-cell type 1 cytokine 
response, but also a suppressor of the type 2 cytokine phenotype. Data about anti-AdV effect 
in cell culture experiments are very controversial. It was established that its activity is limited 
to AdVs of group C and strongly cell culture-dependent [36]. However, the plasma concentra-
tions reached by ribavirin are 10 times below the required IC
50
 value [36, 37].
3. Nonnucleoside compounds
3.1. Abitylguanide
N′N′-anhydro-bis(β-hydroxy-ethyl)biguanide-HCl (abitylguanide) suppressed markedly 
the replication of a large spectrum of human AdVs, both standard laboratory strains and 
strains isolated from epidemic keratoconjunctivitis patients. The magnitude of inhibitory 
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effect varied from 1.5 to 3.8 logs. A marked correlation was established between the value of 
inhibitory effect and belonging of tested AdVs to various subgroups, the strongest activity 
being found toward viruses of subgroup C (Rosen’s subgroup III). The compound susceptible 
period of AdV 5 replication included the total growth cycle, but is especially pronounced dur-
ing the exponential phase. This was established through timing-of-addition study in primary 
cell cultures of human embryo kidney cells. Electron microscopy study of AdV5 morpho-
genesis contributed substantially to the clearing-up of the mechanism of anti-AdV action of 
abitylguanide. It was registered that: (1) the compound decreased about 10-fold the percent-
age of cells in which mature or empty virions with the characteristic nuclear localization were 
observed; (2) a complete absence of paracrystals; (3) the number of cells with virus particles 
arranged in crystals in the nucleoplasm was strongly decreased [38].
The absence of crystalline inclusions established electron microscopically in our study cor-
related with the established pronounced decrease of infectivity and/or lower yields of viral 
progeny which is in line with the meaning [39] that the protein crystals might be involved 
in at late steps of the virus life cycle ensuring correct capsid assembly, virus maturation and 
infectivity. Discussing the mode of action of abitylguanide on AdV 5 replication it has to stress 
on the full coincidence of the data obtained electron microscopically with the results of the 
timing-of-addition study demonstrating the highly-pronounced compound-sensitivity of the 
virus growth in the exponential phase. On the basis of the mentioned data, abitylguanide can 
be considered a ligand of AdV capsid protein(s) [38].
3.2. Trisubstituted piperazin-2-one derivative 15D8
This piperazinone is a result of a large screening of low-molecular substances, embracing 
chemical libraries of in total more than 25,000 compounds. A prospective selection of the com-
pounds was based on protein-protein and protein-DNA interaction [40, 41]. The derivative 
15D8 showed substantial anti-AdV activity (AdV 5 and AdV16 models) in dose-dependent 
manner at high MOI (15,000 vp/cell) with little or absent cytotoxicity at low micromolar 
concentration. The compound selectively inhibits AdV DNA replication in the nucleus. It is 
possible 15D8 to interact with viral proteins essential for DNA, including precursor of the 
terminal protein (pTP), AdV DNA polymerase or the DNA-binding protein (DBP). 15D8 
could be considered as a potential candidate for the development of a new class of antiviral 
compounds to treat AdV infections [42].
3.3. Cardiotonic steroids—digoxin and digitoxin
Very surprising recently (2017), the cardiotonic steroids entered in the scope of the struggle 
with AdV infections. As a theoretic prerequisite of their effects were the data on dependents 
of AdV on the host pre-RNA splicing machinery for expression of its complete genome. On 
such base modulators of RNA splicing as digoxin and digitoxin could be considered as antivi-
rals versus human AdVs. Grosso et al. [3] proved that both drugs reduced of a series of AdVs 
of four different species (A to D) by 2–3 logs. This is a result of affecting several steps needed 
for AdV genome replication (late proteins E4 or f6 and the major late capsid hexon protein is 
compromised). The authors proved that these two drugs altered EiA RNA splicing early in 
infection and partially blocked the translation from 12S and 13S to 9S RNA at later stages of 
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viral replication. By blocking AdV replication at one or more steps beyond the onset of E1A 
expression and before genome replication, digoxin and digitoxin manifest very prospective 
potential as antivirals for the treatment of serious AdV infections.
Convallatoxin, a synthetic cardiotonic steroid, manifested a stronger activity versus AdV5 
when compared with digoxin and digitoxin. In general, these three substances alter the cascade 
of AdV gene expression—an effect starting after initiation of early gene expression attaining a 
blocking of AdV DNA replication and of viral structural proteins. These findings open a novel 
approach of treating AdV infections and guide the development of novel antiviral therapies.
3.4. NMSO
3
 (sulfated sialic acid derivative)
This compound inhibits selectively cellular binding sites (sialic acid-containing receptors) of 
several AdV serotypes. It was established that ADVs possess this cellular tropism. NMSO
3
 
could be used for the topical treatment of ocular AdV infections [43, 44].
3.5. 2,4,5,7-tetranitro-9-fluorenone
This substance markedly inhibits the AdV cystein protease, indispensable for the production 
of infectious AdV virions [45, 46].
3.6. ARD-209 (ADENOVIR)
As a result of the studies carried out by G. Wadell, N. Arnberg and others in University of 
Umea in Sweden (2014–2017), O. Sterner and U. Ellervik (University of Lund, Sweden) syn-
thesized the substance APD-209, announced as ADENOVIR (Pharma). It was noted that this 
substance with unknown structure for the publicity is considered as a new solution for the 
treatment of viral eye infections [47].
Other Swedish authors [48] reported also that analogues of 2-[2-(benzoylamino)benzoyl 
amino]benzoic acid possess inhibitory effect on adenovirus replication.
3.7. Short interfering RNAs
In the search for discovery of efficient anti-AdV agents it was investigated the probable impact 
of silencing of a set of early, middle and late viral genes on the replication of AdV5 in vitro 
[49]. It was established that AdV replication was inhibited by siRNAs directed against AdV 
E1A, DNA polymerase, preterminal protein (pTR), IVa2, hexon, and protease genes. Besides, 
silencing of the early and middle genes was more effective in inhibiting AdV replication than 
the silencing of late genes, especially sharply manifested with effect on siRNA of the DNA 
polymerase gene. Besides, it was found that reducing the viral genome copy numbers (AdV 
DNA) is a more promising strategy than the reducing the number of proteins necessary for 
capsid formation.
3.8. Other compounds inhibiting AdV replication in vitro
Cyclic D,L-α-peptides, cycloferon, lactoferrin nitric oxide, doxovir, heterocyclic Schiff bases 
of aminohydroxyguanidine tosylate, PGD peptidomimetic molecules, some medical plant 
substances (ref. in [17]).
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4. Clinical trials
Prophylaxis with effective antivirals versus AdV EKC would be particularly useful for pre-
venting AdV transmission to the second eye as well as to the contact persons.
Cidofovir eye drops 1% prevent severe corneal opacities in EKC patients, dose-dependent 
local toxicity at frequent administration been registered [50, 51]. This anomalous nucleoside 
at concentration of 1% applied topically in a combination with 1% cyclosporine demonstrated 
therapeutic effect on patients with EKC in a controlled clinical pilot study [51]. No placebo-
controlled randomized trials have been carried out on immunocompromised patients.
Controversial results were obtained with cidofovir the treatment of AdV infections in chil-
dren undergoing bone marrow or stem cell transplantation [52]. Evidence was accumulated 
that as earlier AdV infection is detected for starting cidofovir treatment the better curative 
results were registered. Although cidofovir exhibits antiviral activity versus all AdV species, 
it possesses low oral bioavailability and significant toxicity (tubular necrosis) and does not 
confer long-term protection [53].
However, the lipid conjugate of cidofovir, brincyclovir (BCV; hexadecyloxy propyl-cidofovir; 
CMX001) is currently in Phase II clinical trial [25, 54], unfortunately manifesting a significant 
toxicity to the kidney and gastrointestinal tract.
The topical ganciclovir application against EKC [55] merits special attention. In a pub-
lished clinical study, treatment with 0.15% GCV ophthalmic gel improved outcome of AdV 
conjunctivitis [56]. Three other clinical trials evaluating 0.15% GCV ophthalmic gel were 
organized, two of them finished: (1) Efficacy and Safety of GV 550 in Acute Adenovirus 
Keratoconjunctivitis (Clinical Trials.gov. trial NCT01156025) and (2) Efficacy and Safety 
of GV 550 in Acute Adenovirus Keratoconjunctivitis (a Clinicaltrialsregister.eu trial). Both 
included placebo and treatment groups on 40 persons each (in fact Phase II of clinical trial). 
In the third trial, Clinical Trials.gov trial NCT1533480 (A Placebo Controlled Comparison of 
Topical ZIRGAN Versus Genteal for the treatment of Adenovirus Conjunctivitis) which is 
currently in course, GCV is administered topically as 0.15% gel (ZIRGAN®) compared with 
0.3% Hypromellose gel (Genteal gel®), serving as placebo (Phase IV).
On the base of the promising results with povidone-iodine (PVP-I), a microbicidal agent pos-
sessing also virucidal properties [57], topical ganciclovir and PVP-I combination drops have 
shown the most recent potential, but both therapeutics need to be investigated in larger scale 
studies [58].
The experimental data in vivo are in favor of GCV to be considered as an option for the treat-
ment of AdV infections in immunocompromised patients.
Ribavirin efficacy for the treatment of AdV infections was very controversial [36, 59].
N-chlorotaurine (a week oxidant) manifested effectivity in phase II clinical trials with viral 
conjunctivitis [60].
During a severe outbreak of EKC caused by AdV 8 in 1972–1973 in Bulgaria abitylguanide 
was tested in two double-blind, randomized trials, carried out on total 349 patients (trial 
1–151 patients; trial 2–198 patients) with virologically confirmed diagnosis.
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Abitylguanide was applied as 1% eye drops (in saline). In each of the two trials, patients were 
divided in three groups: group I placebo (patients with symptomatic treatment), group II 
-abitylguanide 1% + symptomatic treatment, group III—patients treated with abitylguanide 
1% only. Curative effect of abitylguanide was almost identical in group II and III in both trials. 
Moreover, the drug had a preventive effect on infection of the second eye. The abitylguanide 
treatment exerted a marked curative effect on the severity and duration of the disease: (1) 
more than twofold decrease in both trials in the number of patients with EKC form associated 
with keratitis; (2) five- and sixfold decrease in trial 1 an trial 2, respectively, in the incidence 
of severe keratitis; (3) two- and fivefold decrease in trial 1 and trial 2, respectively, in the 
number of patients with impaired vision; (4) twofold decrease of the healing time [61–63]. 
Effectivity toward AdV-induced EKC of the drug applied topically was confirmed in series of 
placebo controlled trials (not following the double-blind scheme) in three other ophthalmic 
clinics in the country, carried out in the second half of the 1980s. Pencheva et al. [64] in the 
Varna Medical Faculty registered marked decrease of the patients number with keratitis, two-
fold shortening of the healing time in abitylguanide treated patients, affection of the second 
eye—80% in the placebo group, and 22.6% in abitylguanide treated group.
In preliminary carried out study abitylguanide manifested a very high local tolerance (1, 2 
and 3% eye drops in saline) tested in 21 volunteers (in rabbits—till 20% eye drop).
The pronounced effect of abitylguanide [65] in abovementioned trials on EKC patients 
served for the development and implementation in pharmaceutical industry of preparative 
ADENOSTATIN COLLYRIUM® (Pharmachim Ltd., Sofia) which clinical use marked favor-
able estimation by ophthalmologists in this country (tested in Japan, as well).
The clinical use of cardiotonic steroids as anti-AdV agents needs special consideration. As 
digitoxin has been associated with toxicity, the use of cardiac glycosides as antivirals would 
be short term, in contrast to the chronic use in patients with heart diseases. Having in mind 
that anti-AdV agents have to be used for the treatment of severe respiratory and disseminated 
diseases, these drugs seem more attractive as potential agents for the topical treatment of EKC 
and even for the prophylaxis of persons contact to EKC patients [3].
There is no doubt that chemotherapy of AdV infections occupies leading position as a tool 
for anti-etiological treatment. Therefore, the development of effective anti-AdV agents is espe-
cially a big task of the scientists and clinicians. The above-presented panorama of antivirals 
versus AdVs and AdV-caused infections shows that a lot of work is done for the realization 
of this problem. The author would like to mention the main directions that determined the 
development of antivirals and their implementation in the clinical practice: (1) discovery of 
the targets in virus growth cycle for chemotherapeutic attacks—a lot of “wide” places could be 
pointed in the AdVs; (2) attainment in the organic chemistry—modeling of new effective mol-
ecules with anti-AdV effects among anomalous nucleosides, end especially of non-nucleoside 
compounds ligands of AdV proteins; (3) development of adequate methodology for antiviral 
testing starting from the initial in vitro screening, and application of purified AdV structural 
and eventually nonstructural proteins as cell-free systems (approach contributed substantially 
for the successful development of anti-hepatitis C drugs; as concerns the in vivo testing, in the 
last years, several very convenient and adequate models were described and successfully used 
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(more precisely ocular AdV infections in laboratory animals); (4) application of methods for 
express diagnostic of ADV infections, in order earliest start of the respective treatment with 
anti-AdV chemotherapeutic agents. More detailed consideration of this topic was presented 
by Kaufman [66] and Luchs [67].
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